Across TCGA pan-cancer cohorts, KRT6B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRT6B data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KRT6B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRT6B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LGG, and UCEC are the cancer types where KRT6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.036	0.768	<.001	9	view →
LGG	OS	Median	All	0.147	0.799	<.001	6	view →
UCEC	DFS	Median	All	0.934	0.618	.019	6	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
SKCM	OS	Median	III,IV	0.312	0.729	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KRT6B tumor-vs-normal RNA expression · all KRT6B data types